1-20 of 41
Eiki Ichihara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT106: Phase I/II study of osimertinib in EGFR exon 20 insertion mutations in non-small cell lung cancer patients: AEX20

Eiki Ichihara, Hiroyuki Yasuda, Yuta Takashima, Yoshitaka Zenke, Shinji Takeuchi, Masahiro Morise, Katsuyuki Hotta, Mineyoshi Sato, Shingo Matsumoto, Azusa Tanimoto, Reiko Matsuzawa, Katsuyuki Kiura, Hideki Terai, Shinnosuke Ikemura, Koichi Goto, Kenzo Soejima
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT106.
https://doi.org/10.1158/1538-7445.AM2021-CT106
Published: 01 July 2021
View article titled, Abstract CT106: Phase I/II study of osimertinib in EGFR exon 20 insertion mutations in non-small cell lung cancer patients: AEX20
Journal Articles

Abstract 2131: Significant combination benefit of anti-VEGFR antibody and oncogene-targeted agents in EGFR or ALK mutant NSCLC cells

Hiromi Watanabe, Eiki Ichihara, Hiroe Kayatani, Hisao Higo, Go Makimoto, Hirohisa Kano, Kazuya Nishii, Naofumi Hara, Kiichiro Ninomiya, Toshio Kubo, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2131.
https://doi.org/10.1158/1538-7445.AM2019-2131
Published: 01 July 2019
View article titled, Abstract 2131: Significant combination benefit of anti-VEGFR antibody and oncogene-targeted agents in EGFR or ALK mutant NSCLC cells
Journal Articles

Abstract 1160: The novel osimertinib resistant lung cancer mice model harboring EGFR mutations driven by the SP-C promoter

Kadoaki Ohashi, Hisao Higo, Go Makimoto, Kenichiro Kudo, Kazuya Nishii, Kiichiro Ninomiya, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1160.
https://doi.org/10.1158/1538-7445.AM2018-1160
Published: 01 July 2018
View article titled, Abstract 1160: The novel osimertinib resistant lung cancer mice model harboring EGFR mutations driven by the SP-C promoter
Journal Articles

Abstract 4818: In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M

Kazuya Nishii, Kadoaki Ohashi, Go Makimoto, Hisao Higo, Kiichiro Ninomiya, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4818.
https://doi.org/10.1158/1538-7445.AM2018-4818
Published: 01 July 2018
View article titled, Abstract 4818: In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M
Journal Articles

Abstract 3164: A comprehensive analysis of autopsied specimens and patient-derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib

Go Makimoto, Kadoaki Ohashi, Kazuya Nishii, Shuta Tomida, Hiroe Kayatani, Tomoki Tamura, Hisao Higo, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3164.
https://doi.org/10.1158/1538-7445.AM2017-3164
Published: 01 July 2017
View article titled, Abstract 3164: A comprehensive analysis of autopsied specimens and patient-derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib
Journal Articles

Abstract 3152: Acquired resistance to the third-generation EGFR inhibitor ASP8273 is associated with MET or NRAS gene amplifications in preclinical models

Kiichiro Ninomiya, Kadoaki Ohashi, Shuta Tomida, Hiroe Kayatani, Tomoki Tamura, Hisao Higo, Go Makimoto, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3152.
https://doi.org/10.1158/1538-7445.AM2017-3152
Published: 01 July 2017
View article titled, Abstract 3152: Acquired resistance to the third-generation EGFR inhibitor ASP8273 is associated with MET or NRAS gene amplifications in preclinical models
Journal Articles

Abstract 3160: Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models of EGFR-mutant cancer

David Westover, Catherine B. Meador, Eiki Ichihara, Hayden F. Byrd, Cath Eberlein, Yingjun Yan, Darren A. Cross, Christine M. Lovly
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3160.
https://doi.org/10.1158/1538-7445.AM2017-3160
Published: 01 July 2017
View article titled, Abstract 3160: Sustained MAPK activation as a mechanism of resistance to osimertinib plus selumetinib in models of <em>EGFR</em>-mutant cancer
Journal Articles

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer

Eiki Ichihara, David Westover, Catherine B. Meador, Yingjun Yan, Joshua A. Bauer, Pengcheng Lu, Fei Ye, Amanda Kulick, Elisa de Stanchina, Robert McEwen, Marc Ladanyi, Darren Cross, William Pao, Christine M. Lovly
Journal: Cancer Research
Series: Author Choice
Cancer Res (2017) 77 (11): 2990–3000.
https://doi.org/10.1158/0008-5472.CAN-16-2300
Published: 31 May 2017
View article titled, SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer
Open the PDF for SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 1889: AXL and EGFR signaling mediate resistance to Crizotinib in non-small cell lung cancer cells harboring the ROS1 fusion gene

Yuka Kato, Kadoaki Ohashi, Eiki Ichihara, Shuuta Tomida, Hiroe Kayatani, Kenichiro Kudo, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Toshiyuki Kozuki, Katsuyuki Hotta, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1889.
https://doi.org/10.1158/1538-7445.AM2016-1889
Published: 15 July 2016
View article titled, Abstract 1889: AXL and EGFR signaling mediate resistance to Crizotinib in non-small cell lung cancer cells harboring the ROS1 fusion gene
Journal Articles

Abstract 2103: Activating alternative receptor tyrosine kinases induced alectinib-resistance in ALK rearranged non-small cell lung cancer cells

Hideko Isozaki, Eiki Ichihara, Masayuki Yasugi, Nagio Takigawa, Kadoaki Ohashi, Toshio Kubo, Takashi Ninomiya, Nobuaki Ochi, Daisuke Minami, Kenichiro Kudo, Yuka Kato, Hiroe Kayatani, Tomoki Tamura, Kiichiro Ninomiya, Toshio Higo, Tsuyoshi Makimoto, Akiko Sato, Katsuyuki Hotta, Kunio Matsumoto, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 2103.
https://doi.org/10.1158/1538-7445.AM2016-2103
Published: 15 July 2016
View article titled, Abstract 2103: Activating alternative receptor tyrosine kinases induced alectinib-resistance in ALK rearranged non-small cell lung cancer cells
Journal Articles

Abstract 4667: pCR induced by triplet therapy with low-dose afatinib, cetuximab and bevcizumab in lung cancer cells harboring EGFR T790M

Kadoaki Ohashi, Kenichiro Kudo, Eiki Ichihara, Hiroe Kayatani, Hisao Higo, Yuka Kato, Yasuko Kurata, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4667.
https://doi.org/10.1158/1538-7445.AM2016-4667
Published: 15 July 2016
View article titled, Abstract 4667: pCR induced by triplet therapy with low-dose afatinib, cetuximab and bevcizumab in lung cancer cells harboring EGFR T790M
Journal Articles

Abstract 250: Interleukin-6 as potential predictive marker for therapeutic effect of Gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations

Tomoki Tamura, Katsuyuki Hotta, Yuka Kato, Takehiro Tanaka, Kouichi Ichimura, Kadoaki Oohashi, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 250.
https://doi.org/10.1158/1538-7445.AM2016-250
Published: 15 July 2016
View article titled, Abstract 250: Interleukin-6 as potential predictive marker for therapeutic effect of Gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations
Journal Articles

Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

Hideko Isozaki, Eiki Ichihara, Nagio Takigawa, Kadoaki Ohashi, Nobuaki Ochi, Masayuki Yasugi, Takashi Ninomiya, Hiromichi Yamane, Katsuyuki Hotta, Katsuya Sakai, Kunio Matsumoto, Shinobu Hosokawa, Akihiro Bessho, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2016) 76 (6): 1506–1516.
https://doi.org/10.1158/0008-5472.CAN-15-1010
Published: 14 March 2016
View article titled, Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases
Open the PDF for Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases in another window
Includes: Supplementary data
Journal Articles

Abstract 768: A kinome-wide siRNA screen identifies modifiers of sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor (TKI), AZD9291, in EGFR mutant lung adenocarcinoma

Eiki Ichihara, Joshua A. Bauer, Pengcheng Lu, Fei Ye, Darren Cross, William Pao, Christine M. Lovly
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 768.
https://doi.org/10.1158/1538-7445.AM2015-768
Published: 01 August 2015
View article titled, Abstract 768: A kinome-wide siRNA screen identifies modifiers of sensitivity to the EGFR T790M-targeted tyrosine kinase inhibitor (TKI), AZD9291, in EGFR mutant lung adenocarcinoma
Journal Articles

Abstract 1368: The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations

Kenichiro Kudo, Kadoaki Ohashi, Eiki Ichihara, Daisuke Minami, Hisao Kubo, Akiko Sato, Yuka Kato, Hideko Isozaki, Hiroe Kayatani, Tomoki Tamura, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 1368.
https://doi.org/10.1158/1538-7445.AM2015-1368
Published: 01 August 2015
View article titled, Abstract 1368: The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations
Journal Articles

Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

Catherine A. Eberlein, Daniel Stetson, Aleksandra A. Markovets, Katherine J. Al-Kadhimi, Zhongwu Lai, Paul R. Fisher, Catherine B. Meador, Paula Spitzler, Eiki Ichihara, Sarah J. Ross, Miika J. Ahdesmaki, Ambar Ahmed, Laura E. Ratcliffe, Elizabeth L. Christey O'Brien, Claire H. Barnes, Henry Brown, Paul D. Smith, Jonathan R. Dry, Garry Beran, Kenneth S. Thress, Brian Dougherty, William Pao, Darren A.E. Cross
Journal: Cancer Research
Series: Author Choice
Cancer Res (2015) 75 (12): 2489–2500.
https://doi.org/10.1158/0008-5472.CAN-14-3167
Published: 14 June 2015
View article titled, Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Open the PDF for Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract 3721: ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene

Hideko Isozaki, Eiki Ichihara, Masayuki Yasugi, Ochi Nobuaki, Katsuyuki Hotta, Nagio Takigawa, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 3721.
https://doi.org/10.1158/1538-7445.AM2014-3721
Published: 01 October 2014
View article titled, Abstract 3721: ALK inactivation induced acquired resistance to alectinib in lung cancer harboring EML4-ALK fusion gene
Journal Articles

Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells

Kazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, Junichi Soh, Masaru Jida, Kelsie L. Thu, Shinsuke Hashida, Yuho Maki, Eiki Ichihara, Hiroaki Asano, Kazunori Tsukuda, Nagio Takigawa, Katsuyuki Kiura, Adi F. Gazdar, Wan L. Lam, Shinichiro Miyoshi
Journal: Cancer Research
Series: Author Choice
Cancer Res (2013) 73 (10): 3051–3061.
https://doi.org/10.1158/0008-5472.CAN-12-4136
Published: 12 May 2013
View article titled, Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells
Open the PDF for Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell–like Properties in Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Abstract 4460: Acquisition of stem cell-like properties during acquired resistance to epidermal growth factor receptor inhibitors.

Kazuhiko Shien, Shinichi Toyooka, Hiromasa Yamamoto, Junichi Soh, Kelsie L. Thu, Shinsuke Hashida, Yuho Maki, Eiki Ichihara, Hiroaki Asano, Kazunori Tsukuda, Nagio Takigawa, Katsuyuki Kiura, Adi F. Gazdar, Wan L. Lam, Shinichiro Miyoshi
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4460.
https://doi.org/10.1158/1538-7445.AM2013-4460
Published: 15 April 2013
View article titled, Abstract 4460: Acquisition of stem cell-like properties during acquired resistance to epidermal growth factor receptor inhibitors.
Journal Articles

Abstract 4444: Switching oncogene signaling in a highly selective ALK tyrosine kinase inhibitor CH5424802 resistant cells.

Hideko Isozaki, Eiki Ichihara, Masayuki Yasugi, Takashi Ninomiya, Yoshihiro Honda, Toshi Murakami, Daisuke Minami, Yuka Kato, Kenitiro Kudo, Akiko Sato, Katsuyuki Hotta, Nagio Takigawa, Toshiaki Sendo, Mitsune Tanimoto, Katsuyuki Kiura
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4444.
https://doi.org/10.1158/1538-7445.AM2013-4444
Published: 15 April 2013
View article titled, Abstract 4444: Switching oncogene signaling in a highly selective ALK tyrosine kinase inhibitor CH5424802 resistant cells.